✨ Free AI Report
Currax Pharmaceuticals LLC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Currax Pharmaceuticals LLC
Company Research

Currax Pharmaceuticals LLC: Business Overview, Financials & Competitive Analysis

Currax Pharmaceuticals is a specialty biopharmaceutical company dedicated to expanding patient access to clinically differentiated prescription medicines, primarily focused on obesity and smoking—the top two causes of...

Analyst-debate audio for Currax Pharmaceuticals LLC

AskCyborg analysts argue the bull and bear cases for Currax Pharmaceuticals LLC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Specialty pharma leader in obesity and smoking treatment capturing expanding market with leading branded franchise and improving...

Read the full analyst-debate transcript →
Industry GLP-1 Obesity Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 26, 2026
AI-Generated Research
30+ Page Report

Get the Latest Currax Pharmaceuticals LLC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Currax Pharmaceuticals LLC Overview

Pro stress-test →

Currax Pharmaceuticals is a specialty biopharmaceutical company dedicated to expanding patient access to clinically differentiated prescription medicines, primarily focused on obesity and smoking—the top two causes of preventable death in the U.S. The company's portfolio includes CONTRAVE®, the #1 prescribed branded oral weight-loss medication in the US, along with over 20 products including ONZETRA® Xsail®, Silenor®, and Treximet®.

Strategic Profile

Pro stress-test →

In April 2026, Currax expanded patient access to CONTRAVE® through a partnership with Peek Healthcare Technologies via PeekDirect, which offers transparent, upfront pricing at the point of prescription. In March 2026, the company obtained FDA approval for a second manufacturing site for CONTRAVE® to meet rising demand for weight loss drugs. The company positions itself as a patient-first manufacturer leveraging direct-access models and expanded capacity to capture growing obesity treatment market share.

Competitive Landscape

Pro stress-test →

Currax competes in the specialty pharma sector against companies targeting obesity, CNS disorders, and pain management. While dominant in branded oral weight-loss medications, the company faces competition from GLP-1 agonist manufacturers (Novo Nordisk, Eli Lilly) and other obesity treatment providers. The expanding obesity treatment market and Currax's first-mover advantage in non-GLP-1 branded oral medications position it favorably, though GLP-1 dominance represents a significant competitive headwind.

Industry Context

Currax Pharmaceuticals LLC operates in GLP-1 Obesity Drugs.

Key facts

Founded: 2019 · Headquarters: Brentwood, Tennessee, US · Employees: 150+

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Currax Pharmaceuticals LLC.

  • Market-leading position: CONTRAVE® is the #1 prescribed branded oral weight-loss medication in the US in a rapidly expanding obesity treatment market
  • Distribution innovation: (April 2026) PeekDirect partnership enables direct manufacturer-to-patient access with transparent pricing, differentiating from traditional rebate-driven models
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026Expanded CONTRAVE® patient access through PeekDirect partnership with Peek Healthcare Technologies for transparent direct-to-patient pricing
  • March 2026Obtained FDA approval for second CONTRAVE® manufacturing site to meet weight-loss drug demand surge
  • +1 moreTrack every material event for Currax Pharmaceuticals LLC as it happens. Explore monitoring →
Get alerted when Currax Pharmaceuticals LLC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GLP-1 Agonists (Ozempic/Wegovy)Leading GLP-1 weight-loss and diabetes treatments→MounjaroGLP-1 agonist for obesity and diabetes→Contrave AlternativesNon-GLP-1 weight-loss medications and alternatives→

Compare Currax Pharmaceuticals LLC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Currax Pharmaceuticals LLC operates in GLP-1 Obesity Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse GLP-1 Obesity Drugs research →
NEW · MCP server

Ask your AI assistant about Currax Pharmaceuticals LLC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Currax Pharmaceuticals LLC and its top competitor on Cyborg Score”
“What did Currax Pharmaceuticals LLC do this quarter?”
“Is Currax Pharmaceuticals LLC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Currax Pharmaceuticals LLC do?+
Currax Pharmaceuticals is a specialty biopharmaceutical company dedicated to expanding patient access to clinically differentiated prescription medicines, primarily focused on obesity and smoking—the top two causes of...
What is Currax Pharmaceuticals LLC's Cyborg Score?+
Currax Pharmaceuticals LLC has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Currax Pharmaceuticals LLC's main competitors?+
Named competitors include GLP-1 Agonists (Ozempic/Wegovy), Mounjaro, Contrave Alternatives. The full competitive landscape is in the AskCyborg report.
How can I get the full Currax Pharmaceuticals LLC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Currax Pharmaceuticals LLC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Currax Pharmaceuticals LLC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.